EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers

Table 1 Patient characteristics in the discovery cohort

Characteristics	No. (%)
Gender
Male	234 (60.6)
Female	152 (39.4)
Age
≥ 60	157 (40.7)
< 60	229 (59.3)
Cancer type
Non-small cell lung cancer	129 (33.4)
Melanoma	185 (47.9)
Clear cell renal cell carcinoma	35 (9.1)
Bladder cancer	27 (7.0)
Head and neck cancer	10 (2.6)
Drug class
CTLA-4 (mono)	142 (36.8)
PD-(L)1 (mono)	115 (29.8)
CTLA-4 + PD-(L)1 (combo)	129 (33.4)
Best overall response
CR/PR	118 (30.6)
SD	94 (24.4)
PD	163 (42.2)
NE^a	11 (2.8)
Durable clinical benefit
DCB	163 (42.2)
NDB	195 (50.5)
NE^b	28 (7.3)
EPHA7 status
EPHA7-WT	348 (90.2)
EPHA7-MUT	38 (9.8)
Overall patients	386

Abbreviations: CR complete response, CTLA-4 cytotoxic T cell lymphocyte-4, DCB durable clinical benefit, NDB no durable benefit, NE not evaluable, PD progressive disease, PD-(L)1 programmed cell death-1 or programmed death-ligand 1, PR partial response, SD stable disease
^aEleven patients with best overall response not evaluable due to missing data, including four from Miao et al. [25] and seven from Hellmann et al. [27]
^bTwenty-eight patients with durable clinical benefit not evaluable, including 11 missing data and 17 patients who had not progressed but were censored before 6 months of follow-up

ISSN: 1741-7015